FDA Puts on Hold Phase 1 Cellectis Trial Testing CAR T-cell Therapy UCARTCS1A
A Phase 1 trial assessing Cellectis’ investigational CAR T-cell therapy, UCARTCS1A, for the treatment of relapsed or refractory multiple myeloma has…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
LLS Highlights Its Support Programs During Blood Cancer Awareness Month
Throughout September for Blood Cancer Awareness Month, the Leukemia & Lymphoma Society (LLS) is asking the public to join its commitment to research, education, advocacy,…
Melflufen Combo Earns FDA Priority Review for Triple-refractory Myeloma
The U.S. Food and Drug Administration (FDA) has granted priority review to Oncopeptide’s application seeking accelerated approval of melflufen (melphalan flufenamide) plus dexamethasone…
Trial Begins Dosing of ‘Off-the-shelf’ CAR T-cell Therapy for Multiple Myeloma
The first patient has been dosed in a Phase 1/2a trial investigating Precision BioSciences‘ new CAR T-cell therapy candidate, PBCAR269A, for people with relapsed…
Cilta-cel, CAR T-cell Treatment, Named Breakthrough Therapy in China
Legend Biotech and Janssen’s investigational CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel) has been given breakthrough therapy designation in China as a potential…
First-in-class Blenrep Approved by European Commission for Myeloma
The European Commission (EC) has approved Blenrep (belantamab mafodotin), a first-in-class therapy developed by GlaxoSmithKline (GSK) for the treatment of multiple myeloma.
